Role of FFR in ACS Patients: Pressure ACS Registry - Trial NCT05896501
Access comprehensive clinical trial information for NCT05896501 through Pure Global AI's free database. This phase not specified trial is sponsored by The Catholic University of Korea and is currently Not yet recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The Catholic University of Korea
Timeline & Enrollment
N/A
Jan 01, 2020
Jun 30, 2025
Primary Outcome
Rate of Major adverse cardiac events
Summary
Currently, fractional flow reserve (FFR) is regarded as a gold-standard invasive method to
 define lesion-specific ischemia and FFR-guided PCI has been proven to reduce unnecessary
 revascularization and to enhance patient's clinical outcomes. Therefore, current guidelines
 recommend FFR measurement for intermediate coronary stenosis when there is no definite
 evidence of lesion-specific ischemia. However, previous evidences which well demonstrated the
 benefit of FFR-guided strategy were mostly generated from patients with stable coronary
 artery disease.4 FFR may be overestimated and the hemodynamic relevance of a coronary
 stenosis underestimated in patients with acute coronary syndrome (ACS).Its role in ACS
 patients still needs to be defined although several studies have recently published
 addressing the value of FFR-guided PCI in ACS. In fact, recent evidence suggests that culprit
 lesions of patients presenting with a non-ST-segment elevation myocardial infarction that
 were deferred based on a negative FFR have a relatively high event rate, calling into
 question the use of FFR in that patient population.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05896501
Device Trial